Cytochrome P450-derived eicosanoids and vascular dysfunction in coronary artery disease patients

Atherosclerosis

Volumn 227, Issue 2, 2013, Pages 442-448

  Schuck, Robert N ^a   Theken, Katherine N ^a   Edin, Matthew L ^d   Caughey, Melissa ^b   Bass, Almasa ^a   Ellis, Kyle ^a   Tran, Bryant ^a   Steele, Savanna ^a   Simmons, Brian P ^a   Lih, Fred B ^d   Tomer, Kenneth B ^d   Wu, Michael C ^c   Hinderliter, Alan L ^b   Stouffer, George A ^b   Zeldin, Darryl C ^d   Lee, Craig R ^a,b  

^a University of North Carolina   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c IL   (United States)

^d NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

20 Hydroxyeicosatetraenoic acid; Endothelial function; Epoxyeicosatrienoic acid; Inflammation; Soluble epoxide hydrolase

Indexed keywords

20 HYDROXYICOSATETRAENOIC ACID; ALKANE 1 MONOOXYGENASE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; CHEMOATTRACTANT; CYTOCHROME P450; DIHYDROXYICOSATRIENOIC ACID; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; EPOXIDE HYDROLASE; EPOXYICOSATRIENOIC ACID; ICOSANOID; ICOSATRIENOIC ACID; PADGEM PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANGIOGRAPHY; ARTERY BLOOD FLOW; ARTICLE; ATHEROSCLEROSIS; BRACHIAL ARTERY; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; ENZYME METABOLISM; FATTY ACID METABOLISM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; METABOLISM; MONOCYTE; NEUTROPHIL; PHENOTYPE; PRIORITY JOURNAL; VASCULAR DISEASE;

AGED; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; EICOSANOIDS; ENDOTHELIUM, VASCULAR; EPOXIDE HYDROLASES; FEMALE; HUMANS; HYDROXYEICOSATETRAENOIC ACIDS; INFLAMMATION; MALE; MIDDLE AGED; PHENOTYPE; PROGNOSIS;

EID: 84875052505     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.01.034     Document Type: Article

References (30)

1. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005, 352:1685-1695.
2. Ridker P.M., Cannon C.P., Morrow D., et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005, 352:20-28.
3. de Lemos J.A., Morrow D.A., Blazing M.A., et al. Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial. J Am Coll Cardiol 2007, 50:2117-2124.
4. Blankenberg S., Rupprecht H.J., Bickel C., et al. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 2001, 104:1336-1342.
5. Kitta Y., Obata J.E., Nakamura T., et al. Persistent impairment of endothelial vasomotor function has a negative impact on outcome in patients with coronary artery disease. J Am Coll Cardiol 2009, 53:323-330.
6. Deng Y., Theken K.N., Lee C.R. Cytochrome P450 epoxygenases, soluble epoxide hydrolase, and the regulation of cardiovascular inflammation. J Mol Cell Cardiol 2010, 48:331-341.
7. Roman R.J. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 2002, 82:131-185.
8. Seubert J.M., Sinal C.J., Graves J., et al. Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. Circ Res 2006, 99:442-450.
9. Cheng J., Wu C.C., Gotlinger K.H., et al. 20-Hydroxy-5,8,11,14-eicosatetraenoic acid mediates endothelial dysfunction via IkappaB kinase-dependent endothelial nitric-oxide synthase uncoupling. J Pharmacol Exp Ther 2010, 332:57-65.
10. Node K., Huo Y., Ruan X., et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 1999, 285:1276-1279.
11. Deng Y., Edin M.L., Theken K.N., et al. Endothelial CYP epoxygenase overexpression and soluble epoxide hydrolase disruption attenuate acute vascular inflammatory responses in mice. FASEB J 2011, 25:703-713.
12. Zhang L.N., Vincelette J., Cheng Y., et al. Inhibition of soluble epoxide hydrolase attenuated atherosclerosis, abdominal aortic aneurysm formation, and dyslipidemia. Arterioscler Thromb Vasc Biol 2009, 29:1265-1270.
13. Liu X., Zhao Y., Wang L., et al. Overexpression of cytochrome P450 4F2 in mice increases 20-hydroxyeicosatetraenoic acid production and arterial blood pressure. Kidney Int 2009, 75:1288-1296.
14. Spiecker M., Darius H., Hankeln T., et al. Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2. Circulation 2004, 110:2132-2136.
15. Lee C.R., North K.E., Bray M.S., et al. Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. Hum Mol Genet 2006, 15:1640-1649.
16. Ward N.C., Tsai I.J., Barden A., et al. A single nucleotide polymorphism in the CYP4F2 but not CYP4A11 gene is associated with increased 20-HETE excretion and blood pressure. Hypertension 2008, 51:1393-1398.
17. Theken K.N., Schuck R.N., Edin M.L., et al. Evaluation of cytochrome P450-derived eicosanoids in humans with stable atherosclerotic cardiovascular disease. Atherosclerosis 2012, 222:530-536.
18. Chen D., Whitcomb R., MacIntyre E., et al. Pharmacokinetics and pharmacodynamics of AR9281, an inhibitor of soluble epoxide hydrolase, in single- and multiple-dose studies in healthy human subjects. J Clin Pharmacol 2012, 52:319-328.
19. Williams J.M., Murphy S., Burke M., Roman R.J. 20-hydroxyeicosatetraeonic acid: a new target for the treatment of hypertension. J Cardiovasc Pharmacol 2010, 56:336-344.
20. Lee C.R., Bass A., Ellis K., et al. Relation between digital peripheral arterial tonometry and brachial artery ultrasound measures of vascular function in patients with coronary artery disease and in healthy volunteers. Am J Cardiol 2012, 109:651-657.
21. Zineh I., Beitelshees A.L., Welder G.J., et al. Epithelial neutrophil-activating peptide (ENA-78), acute coronary syndrome prognosis, and modulatory effect of statins. PLoS One 2008, 3:e3117.
22. Ward N.C., Rivera J., Hodgson J., et al. Urinary 20-hydroxyeicosatetraenoic acid is associated with endothelial dysfunction in humans. Circulation 2004, 110:438-443.
23. Ishizuka T., Cheng J., Singh H., et al. 20-Hydroxyeicosatetraenoic acid stimulates nuclear factor-kappaB activation and the production of inflammatory cytokines in human endothelial cells. J Pharmacol Exp Ther 2008, 324:103-110.
24. Bystrom J., Wray J.A., Sugden M.C., et al. Endogenous epoxygenases are modulators of monocyte/macrophage activity. PLoS One 2011, 6:e26591.
25. Fromel T., Jungblut B., Hu J., et al. Soluble epoxide hydrolase regulates hematopoietic progenitor cell function via generation of fatty acid diols. Proc Natl Acad Sci U S A 2012, 109:9995-10000.
26. Lee C.R., Pretorius M., Schuck R.N., et al. Genetic variation in soluble epoxide hydrolase (EPHX2) is associated with forearm vasodilator responses in humans. Hypertension 2011, 57:116-122.
27. Fichtlscherer S., Dimmeler S., Breuer S., Busse R., Zeiher A.M., Fleming I. Inhibition of cytochrome P450 2C9 improves endothelium-dependent, nitric oxide-mediated vasodilatation in patients with coronary artery disease. Circulation 2004, 109:178-183.
28. Larsen B.T., Gutterman D.D., Sato A., et al. Hydrogen peroxide inhibits cytochrome p450 epoxygenases: interaction between two endothelium-derived hyperpolarizing factors. Circ Res 2008, 102:59-67.
29. Tracy R.P., Psaty B.M., Macy E., et al. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb Vasc Biol 1997, 17:2167-2176.
30. Fife K.L., Liu Y., Schmelzer K.R., et al. Inhibition of soluble epoxide hydrolase does not protect against endotoxin-mediated hepatic inflammation. J Pharmacol Exp Ther 2008, 327:707-715.